The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease
Status:
Unknown status
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to examine the efficacy of 1gram/day intravenous pulses of
methylprednisolone on 3 consecutive days in Behcet's patients with ocular involvement. A
total of 34 Behcet's patients referring to Behcet's clinic in Shariati hospital whose problem
was confirmed with new international criteria of Behcet's disease (ICBD) will be randomly
assigned into one of the two equal groups of intervention or control. Behcet's patients are
those with ocular involvement who were under the same cytotoxic treatment with
cyclophosphamide and azathioprine. For the patients in the intervention group, intravenous
infusion of 1000 mg methylprednisolone in 100cc D/w 5% or 100cc D/w5% on 3 consecutive days
will be added to treatment diet. Then treatment will begin with oral prednisolone, 0.5 mg/kg.
After that, all the patients were followed up with no other therapeutic intervention by study
group. The patients will be visited every 2 months by an ophthalmologist and study group for
6 months in 3 settings. To estimate the ocular inflammation of patients, we use visual
acuity, retinal and ocular posterior chamber inflammation index.